Encrantz Staffan 4

What Happened

• Staffan Encrantz, a director of Sight Sciences, Inc. (SGHT) and reported 10% owner, was granted 28,261 restricted stock units (RSUs) on June 4, 2026. The Form 4 reports an acquisition at $0.00 per share (award/grant). The grant was valued at approximately $130,000 based on the closing price on the grant date. Each RSU represents a contingent right to one share of common stock and vests on the earlier of June 4, 2027 or the Company’s 2027 annual meeting, subject to continued service.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely).
• Transaction type/code: Award/Grant (A); reported acquisition price $0.00.
• Shares granted: 28,261 RSUs (vesting contingent as noted above).
• Reported holdings after transaction: 1,391,922 shares of common stock plus 28,261 RSUs subject to vesting (per filing footnote).
• Notable footnotes: Grant made under the issuer’s Non‑Employee Director Compensation Program. Some reported shareholdings are held by a family trust (Reporting Person is a trustee) and by Allegro Investment Fund, L.P.; the reporting person disclaims beneficial ownership of certain fund/trust shares except to the extent of any pecuniary interest.

Context

• RSU grants are compensation awards, not open‑market purchases or sales; they don’t involve cash paid by the grantee and only convert to shares if and when they vest. Such awards are routine for non‑employee directors and reflect compensation rather than an immediate trading signal. As a reported 10% owner and director, Encrantz’s filing also discloses related holdings held in trust and an investment fund (with disclaimers of beneficial ownership).